Austedo deutetrabenazine

Access collapse at the specialty-pharmacy step is the single biggest adherence threat for Austedo, outweighing clinical side-effect concerns in real patient conversation.

• Cost and specialty-pharmacy friction dominate patient conversation far more than any side effect, with cash prices of $7,000-$10,000/month creating a permanent anxiety layer throughout the treatment journey.
• Depression and suicidal ideation emerge rapidly in some patients (within days), creating an acute early-discontinuation cliff that the boxed warning alone does not appear to fully prepare patients or caregivers for.
• Titration is widely perceived as a meaningful clinical benefit, especially by HD caregivers, but the multi-tablet complexity of the BID formulation drove real adherence gaps that the XR launch directly addressed.
• INGREZZA (valbenazine) is gaining persistence advantage in real-world claims data, and Austedo XR must close the gap through stronger patient-support infrastructure and proactive peer-mentorship touchpoints.